{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:38:02Z","timestamp":1790228282373,"version":"4.1.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council UK","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust (G.R.S.)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.coviro.2017.04.002","type":"journal-article","created":{"date-parts":[[2017,5,6]],"date-time":"2017-05-06T18:03:47Z","timestamp":1494093827000},"page":"95-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Recent advances in human flavivirus vaccines"],"prefix":"10.1016","volume":"23","author":[{"given":"Iris","family":"Scherwitzl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juthathip","family":"Mongkolsapaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Screaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2017.04.002_bib0005","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/IJGM.S59902","article-title":"A review of the epidemiological and clinical aspects of West Nile virus","volume":"7","author":"Gray","year":"2014","journal-title":"Int. J. Gen. Med."},{"key":"10.1016\/j.coviro.2017.04.002_bib0010","unstructured":"CDC: West Nile Virus. https:\/\/www.cdc.gov\/westnile\/statsmaps\/index.html, 2016."},{"key":"10.1016\/j.coviro.2017.04.002_bib0015","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2017.04.002_bib0020","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.6233.1","article-title":"Recent advances in understanding dengue","volume":"5","author":"Yacoub","year":"2016","journal-title":"F1000Research"},{"key":"10.1016\/j.coviro.2017.04.002_bib0025","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s00705-013-1645-3","article-title":"Secondary infection as a risk factor for dengue hemorrhagic fever\/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection","volume":"158","author":"Guzman","year":"2013","journal-title":"Arch. Virol."},{"key":"10.1016\/j.coviro.2017.04.002_sbref0030","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/265739a0","article-title":"Antibody-enhanced dengue virus infection in primate leukocytes","volume":"265","author":"Halstead","year":"1977","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2017.04.002_sbref0035","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/nm887","article-title":"Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever","volume":"9","author":"Mongkolsapaya","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.coviro.2017.04.002_bib0040","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1126\/science.1185181","article-title":"Cross-reacting antibodies enhance dengue virus infection in humans","volume":"328","author":"Dejnirattisai","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.coviro.2017.04.002_bib0045","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/ni.3058","article-title":"A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus","volume":"16","author":"Dejnirattisai","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.coviro.2017.04.002_bib0050","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.chom.2010.08.007","article-title":"The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity","volume":"8","author":"Beltramello","year":"2010","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.coviro.2017.04.002_bib0055","doi-asserted-by":"crossref","first-page":"11726","DOI":"10.1128\/JVI.01140-14","article-title":"Combined effects of the structural heterogeneity and dynamics of flaviviruses on antibody recognition","volume":"88","author":"Dowd","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.coviro.2017.04.002_bib0060","doi-asserted-by":"crossref","first-page":"7585","DOI":"10.1128\/JVI.00757-13","article-title":"Structural changes in dengue virus when exposed to a temperature of 37\u00b0C","volume":"87","author":"Fibriansah","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.coviro.2017.04.002_bib0065","doi-asserted-by":"crossref","first-page":"6795","DOI":"10.1073\/pnas.1304300110","article-title":"Dengue structure differs at the temperatures of its human and mosquito hosts","volume":"110","author":"Zhang","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.coviro.2017.04.002_bib0070","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1128\/CMR.00072-15","article-title":"Zika virus","volume":"29","author":"Musso","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.coviro.2017.04.002_sbref0075","doi-asserted-by":"crossref","first-page":"4864","DOI":"10.1128\/JVI.00252-16","article-title":"Zika virus: new clinical syndromes and its emergence in the western hemisphere","volume":"90","author":"Lazear","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.coviro.2017.04.002_bib0080","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1056\/NEJMoa1600651","article-title":"Zika virus associated with microcephaly","volume":"374","author":"Mlakar","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.coviro.2017.04.002_bib0085","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S0140-6736(16)00562-6","article-title":"Guillain\u2013Barre syndrome outbreak associated with Zika virus infection in French polynesia: a case-control study","volume":"387","author":"Cao-Lormeau","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2017.04.002_bib0090","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrmicro1067","article-title":"A structural perspective of the flavivirus life cycle","volume":"3","author":"Mukhopadhyay","year":"2005","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.coviro.2017.04.002_bib0095","doi-asserted-by":"crossref","first-page":"13097","DOI":"10.1128\/JVI.76.24.13097-13100.2002","article-title":"Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein","volume":"76","author":"Beasley","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.coviro.2017.04.002_bib0100","doi-asserted-by":"crossref","first-page":"7769","DOI":"10.1128\/JVI.75.16.7769-7773.2001","article-title":"Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells","volume":"75","author":"Crill","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.coviro.2017.04.002_bib0105","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nri3916","article-title":"New insights into the immunopathology and control of dengue virus infection","volume":"15","author":"Screaton","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.coviro.2017.04.002_bib0110","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nature14130","article-title":"Recognition determinants of broadly neutralizing human antibodies against dengue viruses","volume":"520","author":"Rouvinski","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2017.04.002_bib0115","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1297-9716-43-16","article-title":"Recent progress in West Nile virus diagnosis and vaccination","volume":"43","author":"De Filette","year":"2012","journal-title":"Vet. Res."},{"key":"10.1016\/j.coviro.2017.04.002_bib0120","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1084\/jem.20031223","article-title":"A critical role for induced IgM in the protection against West Nile virus infection","volume":"198","author":"Diamond","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.coviro.2017.04.002_bib0125","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1128\/JVI.77.4.2578-2586.2003","article-title":"B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus","volume":"77","author":"Diamond","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.coviro.2017.04.002_bib0130","doi-asserted-by":"crossref","first-page":"8312","DOI":"10.1128\/JVI.78.15.8312-8321.2004","article-title":"Role of CD8+ T cells in control of West Nile virus infection","volume":"78","author":"Shrestha","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.coviro.2017.04.002_bib0135","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1002\/eji.200737196","article-title":"Protective capacity and epitope specificity of CD8(+) T cells responding to lethal West Nile virus infection","volume":"37","author":"Brien","year":"2007","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.coviro.2017.04.002_bib0140","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/j.vaccine.2008.02.009","article-title":"The relative contribution of antibody and CD8+ T cells to vaccine immunity against West Nile encephalitis virus","volume":"26","author":"Shrestha","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2017.04.002_bib0145","doi-asserted-by":"crossref","first-page":"13323","DOI":"10.1128\/JVI.77.24.13323-13334.2003","article-title":"CD8+ T cells mediate recovery and immunopathology in West Nile virus encephalitis","volume":"77","author":"Wang","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.coviro.2017.04.002_bib0150","doi-asserted-by":"crossref","first-page":"e1002698","DOI":"10.1371\/journal.ppat.1002698","article-title":"2\u2032-O methylation of the viral mRNA cap by West Nile virus evades ifit1-dependent and -independent mechanisms of host restriction in vivo","volume":"8","author":"Szretter","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.coviro.2017.04.002_bib0155","doi-asserted-by":"crossref","first-page":"12497","DOI":"10.1128\/JVI.78.22.12497-12507.2004","article-title":"ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy","volume":"78","author":"Arroyo","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.coviro.2017.04.002_bib0160","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.3201\/eid0812.020229","article-title":"Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster model","volume":"8","author":"Tesh","year":"2002","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.coviro.2017.04.002_bib0165","doi-asserted-by":"crossref","first-page":"6694","DOI":"10.1073\/pnas.0601932103","article-title":"A live, attenuated recombinant West Nile virus vaccine","volume":"103","author":"Monath","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.coviro.2017.04.002_sbref0170","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/infdis\/jiq003","article-title":"Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults","volume":"203","author":"Biedenbender","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.coviro.2017.04.002_sbref0175","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1016\/j.vaccine.2012.08.063","article-title":"Phase II, dose ranging study of the safety and immunogenicity of single dose West Nile vaccine in healthy adults >\/=50 years of age","volume":"30","author":"Dayan","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2017.04.002_bib0180","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1016\/j.vaccine.2006.06.008","article-title":"Chimeric West Nile\/dengue virus vaccine candidate: preclinical evaluation in mice, geese and monkeys for safety and immunogenicity","volume":"24","author":"Pletnev","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2017.04.002_bib0185","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1073\/pnas.022652799","article-title":"West Nile virus\/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy","volume":"99","author":"Pletnev","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.coviro.2017.04.002_bib0190","doi-asserted-by":"crossref","first-page":"5772","DOI":"10.1016\/j.vaccine.2013.07.064","article-title":"The live attenuated chimeric vaccine rWN\/DEN4Delta30 is well-tolerated and immunogenic in healthy flavivirus-naive adult volunteers","volume":"31","author":"Durbin","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2017.04.002_sbref0195","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/nm.2763","article-title":"Development of a new hydrogen peroxide-based vaccine platform","volume":"18","author":"Amanna","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.coviro.2017.04.002_bib0200","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1128\/JVI.02903-12","article-title":"A hydrogen peroxide-inactivated virus vaccine elicits humoral and cellular immunity and protects against lethal West Nile virus infection in aged mice","volume":"87","author":"Pinto","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.coviro.2017.04.002_bib0205","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1086\/523650","article-title":"A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial","volume":"196","author":"Martin","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.coviro.2017.04.002_bib0210","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/infdis\/jir054","article-title":"A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial","volume":"203","author":"Ledgerwood","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.coviro.2017.04.002_bib0215","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.vaccine.2006.08.018","article-title":"Preparation and immunogenic properties of a recombinant West Nile subunit vaccine","volume":"25","author":"Lieberman","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2017.04.002_bib0220","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1128\/CVI.00119-09","article-title":"Immunogenicity and protective efficacy of a recombinant subunit West Nile virus vaccine in rhesus monkeys","volume":"16","author":"Lieberman","year":"2009","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.coviro.2017.04.002_bib0225","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1016\/j.vaccine.2006.08.008","article-title":"Efficacy and durability of a recombinant subunit West Nile vaccine candidate in protecting hamsters from West Nile encephalitis","volume":"25","author":"Watts","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2017.04.002_bib0230","unstructured":"Coller BA, Vidya P, Weeks-Levy C, Ogata S: United States Patent Application No. US20120141520 A1: Recombinant Subunit West Nile Virus Vaccine for Protection of Human Subjects, 2012."},{"key":"10.1016\/j.coviro.2017.04.002_bib0235","doi-asserted-by":"crossref","first-page":"7229","DOI":"10.1016\/j.vaccine.2011.06.094","article-title":"From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine","volume":"29","author":"Guy","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2017.04.002_sbref0240","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2017.04.002_sbref0245","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America","volume":"372","author":"Villar","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.coviro.2017.04.002_bib0250","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and long-term safety of a dengue vaccine in regions of endemic disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.coviro.2017.04.002_bib0255","series-title":"Summary of the April Meeting of the Strategic Advisory Group of Experts on immunization (SAGE)","first-page":"1","author":"SAGE","year":"2016"},{"key":"10.1016\/j.coviro.2017.04.002_bib0260","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/infdis\/jis936","article-title":"A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial","volume":"207","author":"Durbin","year":"2013","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.coviro.2017.04.002_bib0265","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/infdis\/jiv082","article-title":"Robust and balanced immune responses to all 4 Dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, flavivirus-naive adults","volume":"212","author":"Kirkpatrick","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.coviro.2017.04.002_sbref0270","doi-asserted-by":"crossref","first-page":"330ra36","DOI":"10.1126\/scitranslmed.aaf1517","article-title":"The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model","volume":"8","author":"Kirkpatrick","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.coviro.2017.04.002_bib0275","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1473-3099(14)70811-4","article-title":"Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study","volume":"14","author":"Osorio","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.coviro.2017.04.002_bib0280","doi-asserted-by":"crossref","first-page":"6351","DOI":"10.1016\/j.vaccine.2015.09.008","article-title":"Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: a phase 1b randomized study","volume":"33","author":"Rupp","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2017.04.002_bib0285","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1093\/infdis\/jiv179","article-title":"Safety and immunogenicity of a live attenuated tetravalent dengue vaccine candidate in flavivirus-naive adults: a randomized, double-blinded phase 1 clinical trial","volume":"212","author":"George","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.coviro.2017.04.002_bib0290","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/infdis\/jiv762","article-title":"Safety and immunogenicity of a tetravalent dengue vaccine candidate in healthy children and adults in dengue-endemic regions: a randomized, placebo-controlled phase 2 study","volume":"213","author":"Sirivichayakul","year":"2016","journal-title":"J. Infect. Dis."},{"issue":"Suppl. 4","key":"10.1016\/j.coviro.2017.04.002_sbref0295","doi-asserted-by":"crossref","first-page":"D24","DOI":"10.1016\/j.vaccine.2015.05.095","article-title":"Trials and tribulations on the path to developing a dengue vaccine","volume":"33","author":"Thomas","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2017.04.002_bib0300","doi-asserted-by":"crossref","first-page":"7267","DOI":"10.1016\/j.vaccine.2011.07.021","article-title":"The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease","volume":"29","author":"Coller","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2017.04.002_bib0305","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.1016\/j.vaccine.2015.09.101","article-title":"Preclinical and clinical development of a dengue recombinant subunit vaccine","volume":"33","author":"Manoff","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2017.04.002_bib0310","doi-asserted-by":"crossref","first-page":"89","DOI":"10.7774\/cevr.2016.5.2.89","article-title":"Prospects for dengue vaccines for travelers","volume":"5","author":"Lim","year":"2016","journal-title":"Clin. Exp. Vaccine Res."},{"key":"10.1016\/j.coviro.2017.04.002_bib0315","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0042-6822(03)00542-7","article-title":"Needle-free biojector injection of a dengue virus type 1 DNA vaccine with human immunostimulatory sequences and the GM-CSF gene increases immunogenicity and protection from virus challenge in Aotus monkeys","volume":"315","author":"Raviprakash","year":"2003","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2017.04.002_bib0320","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1006\/viro.2001.1136","article-title":"Synergistic neutralizing antibody response to a dengue virus type 2 DNA vaccine by incorporation of lysosome-associated membrane protein sequences and use of plasmid expressing GM-CSF","volume":"290","author":"Raviprakash","year":"2001","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2017.04.002_bib0325","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.vaccine.2010.11.050","article-title":"Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial","volume":"29","author":"Beckett","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2017.04.002_bib0330","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.4161\/hv.21806","article-title":"A dengue DNA vaccine formulated with Vaxfectin(R) is well tolerated: and elicits strong neutralizing antibody responses to all four dengue serotypes in New Zealand white rabbits","volume":"8","author":"Raviprakash","year":"2012","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.coviro.2017.04.002_sbref0335","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nature18952","article-title":"Vaccine protection against Zika virus from Brazil","volume":"536","author":"\u2022\u2022] Larocca","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2017.04.002_sbref0340","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1126\/science.aah6157","article-title":"Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys","volume":"353","author":"Abbink","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.coviro.2017.04.002_bib0345","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nature20564","article-title":"Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice","volume":"540","author":"Sapparapu","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2017.04.002_sbref0350","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.chom.2016.12.010","article-title":"Mapping and role of the CD8+ T cell response during primary Zika virus infection in mice","volume":"21","author":"Elong Ngono","year":"2017","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.coviro.2017.04.002_bib0355","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/ni.3515","article-title":"Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with Zika virus","volume":"17","author":"Dejnirattisai","year":"2016","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.coviro.2017.04.002_bib0360","doi-asserted-by":"crossref","first-page":"7852","DOI":"10.1073\/pnas.1607931113","article-title":"Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus","volume":"113","author":"Priyamvada","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.coviro.2017.04.002_bib0365","article-title":"Utility of a dengue-derived monoclonal antibody to enhance Zika infection in vitro","volume":"8","author":"Charles","year":"2016","journal-title":"PLoS Curr."},{"key":"10.1016\/j.coviro.2017.04.002_sbref0370","doi-asserted-by":"crossref","DOI":"10.1126\/science.aal4365","article-title":"Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity","author":"Bardina","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.coviro.2017.04.002_sbref0375","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1126\/science.aai9137","article-title":"Rapid development of a DNA vaccine for Zika virus","volume":"354","author":"Dowd","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.coviro.2017.04.002_bib0380","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nature21428","article-title":"Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination","volume":"543","author":"Pardi","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2017.04.002_bib0385","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.cell.2017.02.017","article-title":"Modified mRNA vaccines protect against Zika virus infection","volume":"168","author":"Richner","year":"2017","journal-title":"Cell"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625716301675?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625716301675?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T13:25:16Z","timestamp":1569245116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625716301675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":77,"alternative-id":["S1879625716301675"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2017.04.002","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in human flavivirus vaccines","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2017.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}